Omalizumab Induced Remission of Idiopathic Anaphylaxis in a Patient Suffering from Indolent Systemic Mastocytosis

Kibsgaard, Line; Skjold, Tina; Deleuran, Mette; Vestergaard, Christian

doi:10.2340/00015555-1687

Cited by 41 publications

(41 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…OmAb has been reported to be safe and effective in preventing recurrent anaphylaxis [73]. Since OmAb reduces the expression of Fc ε RI on circulating basophils and mast cells, it seems to lower their activity and thus reduces their potential reactivity [74, 75]. Curiously, there is no evidence of the capacity of OmAb to decrease mast cell numbers, because the serum tryptase levels in several patients with mastocytosis do not vary during the period of response [76].…”

Section: Anti-ige-based Treatmentsmentioning

confidence: 99%

IgE-Related Chronic Diseases and Anti-IgE-Based Treatments

Navinés-Ferrer

Serrano‐Candelas

Molina-Molina

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

IgE is an immunoglobulin that plays a central role in acute allergic reactions and chronic inflammatory allergic diseases. The development of a drug able to neutralize this antibody represents a breakthrough in the treatment of inflammatory pathologies with a probable allergic basis. This review focuses on IgE-related chronic diseases, such as allergic asthma and chronic urticaria (CU), and on the role of the anti-IgE monoclonal antibody, omalizumab, in their treatment. We also assess the off-label use of omalizumab for other pathologies associated with IgE and report the latest findings concerning this drug and other new related drugs. To date, omalizumab has only been approved for severe allergic asthma and unresponsive chronic urticaria treatments. In allergic asthma, omalizumab has demonstrated its efficacy in reducing the dose of inhaled corticosteroids required by patients, decreasing the number of asthma exacerbations, and limiting the effect on airway remodeling. In CU, omalizumab treatment rapidly improves symptoms and in some cases achieves complete disease remission. In systemic mastocytosis, omalizumab also improves symptoms and its prophylactic use to prevent anaphylactic reactions has also been discussed. In other pathologies such as atopic dermatitis, food allergy, allergic rhinitis, nasal polyposis, and keratoconjunctivitis, omalizumab significantly improves clinical manifestations. Omalizumab acts in two ways: by sequestering free IgE and by accelerating the dissociation of the IgE-Fcε receptor I complex.

show abstract

Section: Anti-ige-based Treatmentsmentioning

confidence: 99%

IgE-Related Chronic Diseases and Anti-IgE-Based Treatments

Navinés-Ferrer

Serrano‐Candelas

Molina-Molina

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Several case reports combining omalizumab with venomspecific immunotherapy to improve the safety of the latter in mastocytosis patients have been published [127][128][129]. Omalizumab has been reported to be safe and effective in preventing recurrent anaphylaxis in several small case series [130][131][132][133][134][135]. The patients showed rapid and long-term efficiency of this treatment to control life-threatening mastocytosis-related symptoms.…”

Section: Anaphylaxismentioning

confidence: 95%

Off-Label Uses of Omalizumab

El-Qutob¹

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The off-label use of medicines is a common and extensive clinical practice. Omalizumab has been licensed for use in severe allergic asthma and chronic urticaria. Omalizumab dosing was based on body weight and baseline serum IgE concentration. All patients are required to have a baseline IgE between 30 and 700 IU/ml and body weight not more than 150 kg. The use of off-label drugs may lead to several problems including adverse effects and an increased risk/benefit balance. In this article, there are summarized off-label uses of omalizumab in the last recent years in diseases in which IgE maybe or certainly has a corner role such as allergic rhinitis, allergic bronchopulmonary aspergillosis, anaphylaxis, keratoconjunctivitis, food allergy, drug allergy, urticaria, angioedema, non-atopic asthma, atopic dermatitis, nasal polyps, Churg-Strauss syndrome, eosinophilic otitis media, chronic rhinosinusitis, bullous pemphigoid, contact dermatitis, and others. Use in pregnancy asthmatic women and pre-co-administration with specific immunotherapy will also be revised.

show abstract

“…69 Given its success in treating other disorders where MC are pathogenically involved, omalizumab can be considered in patients with daily symptoms who have been unresponsive to maximum doses of antihistamines, as described in several case reports. [70][71][72][73] M A N U S C R I P T…”

Section: Indolent Systemic Mastocytosismentioning

confidence: 99%